{"id":"dapiprazole","rwe":[{"pmid":"38846833","year":"2024","title":"Ryzumvi: pioneering advances in countering drug-induced mydriasis.","finding":"","journal":"Annals of medicine and surgery (2012)","studyType":"Clinical Study"},{"pmid":"38829162","year":"2024","title":"Neurokinin-1 Receptor Antagonism Reduces Nonallergic Ocular Redness in a Rabbit Model.","finding":"","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","studyType":"Clinical Study"},{"pmid":"26090217","year":"2015","title":"Pharmacological Isolation of Cognitive Components Influencing the Pupillary Light Reflex.","finding":"","journal":"Journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"24847516","year":"2014","title":"Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"},{"pmid":"23169931","year":"2013","title":"Development and validation of a stability-indicating RP-HPLC assay method and stress degradation studies on dapiprazole.","finding":"","journal":"Journal of chromatographic science","studyType":"Clinical Study"}],"tags":[{"label":"alpha-Adrenergic Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1D adrenergic receptor","category":"target"},{"label":"ADRA1D","category":"gene"},{"label":"HTR2A","category":"gene"},{"label":"HTR2C","category":"gene"},{"label":"S01EX02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Reverse Mydriasis from Ophthalmic Adrenergic or Anticholinergic Agent","category":"indication"},{"label":"Fera Pharms","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Conjunctival injection","drugRate":"80%","severity":"common","organSystem":""},{"effect":"Burning on instillation","drugRate":"50%","severity":"common","organSystem":""},{"effect":"Ptosis","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Lid erythema","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Lid edema","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Chemosis","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Itching","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Punctate keratitis","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Corneal edema","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Browache","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Photophobia","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Headaches","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Dryness of eyes","drugRate":"","severity":"uncommon","organSystem":""},{"effect":"Tearing","drugRate":"","severity":"uncommon","organSystem":""},{"effect":"Blurring of vision","drugRate":"","severity":"uncommon","organSystem":""}],"contraindications":["Angle-closure glaucoma","Iritis"],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Fera Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DAPIPRAZOLE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:11:58.564069+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:06.141310+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DAPIPRAZOLE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:07.279810+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201216/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:07.748613+00:00"}},"allNames":"dapiprazole hydrochloride","offLabel":[],"synonyms":["dapiprazole hydrochloride","dapiprazole","AF-2139","dapiprazole HCl"],"timeline":[{"date":"1990-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from FERA PHARMS to Fera Pharms"},{"date":"1990-12-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Fera Pharms)"},{"date":"2019-05-30","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"approvals":[{"date":"1990-12-31","orphan":false,"company":"FERA PHARMS","regulator":"FDA"}],"brandName":"Dapiprazole Hydrochloride","ecosystem":[{"indication":"Reverse Mydriasis from Ophthalmic Adrenergic or Anticholinergic Agent","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Alpha-1D adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"}],"moaClass":"Adrenergic alpha-Antagonists","modality":"Small Molecule","drugClass":"alpha-Adrenergic Blocker","explanation":"","oneSentence":"","technicalDetail":"Dapiprazole Hydrochloride acts as a selective alpha-1D adrenergic receptor antagonist, competing with endogenous norepinephrine for receptor binding sites and preventing the resulting vasoconstriction and mydriasis."},"commercial":{"launchDate":"1990","_launchSource":"DrugCentral (FDA 1990-12-31, FERA PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/781","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DAPIPRAZOLE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:28:21.197009","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:09.637335+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"guanethidine","drugSlug":"guanethidine","fdaApproval":"1960-07-05","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"netarsudil","drugSlug":"netarsudil","fdaApproval":"2017-12-18","patentExpiry":"Nov 10, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"omidenepag isopropyl","drugSlug":"omidenepag-isopropyl","fdaApproval":"2022-09-22","patentExpiry":"Oct 13, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"dapiprazole","indications":{"approved":[{"name":"Reverse Mydriasis from Ophthalmic Adrenergic or Anticholinergic Agent","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Fera Pharms","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"guanethidine","brandName":"guanethidine","genericName":"guanethidine","approvalYear":"1960","relationship":"same-class"},{"drugId":"netarsudil","brandName":"netarsudil","genericName":"netarsudil","approvalYear":"2017","relationship":"same-class"},{"drugId":"omidenepag-isopropyl","brandName":"omidenepag isopropyl","genericName":"omidenepag isopropyl","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148101","MMSL":"4535","NDDF":"003595","UNII":"5RNZ8GJO7K","VUID":"4020111","CHEBI":"CHEBI:51066","VANDF":"4020111","INN_ID":"4983","RXNORM":"22298","UMLSCUI":"C0057143","chemblId":"CHEMBL1201216","ChEMBL_ID":"CHEMBL1201216","KEGG_DRUG":"D03648","DRUGBANK_ID":"DB00298","PUBCHEM_CID":"3033538","SNOMEDCT_US":"108840006","IUPHAR_LIGAND_ID":"7155","SECONDARY_CAS_RN":"72822-13-0","MESH_SUPPLEMENTAL_RECORD_UI":"C035289"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1990-","companyName":"Fera Pharms","relationship":"Original Developer"}],"publicationCount":69,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01EX02","allCodes":["S01EX02"]},"biosimilarFilings":[],"originalDeveloper":"Fera Pharms","recentPublications":[{"date":"2024 Jun","pmid":"38846833","title":"Ryzumvi: pioneering advances in countering drug-induced mydriasis.","journal":"Annals of medicine and surgery (2012)"},{"date":"2024 Sep","pmid":"38829162","title":"Neurokinin-1 Receptor Antagonism Reduces Nonallergic Ocular Redness in a Rabbit Model.","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"date":"2015","pmid":"26090217","title":"Pharmacological Isolation of Cognitive Components Influencing the Pupillary Light Reflex.","journal":"Journal of ophthalmology"},{"date":"2014 May","pmid":"24847516","title":"Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics.","journal":"Biomedical chromatography : BMC"},{"date":"2013 Oct","pmid":"23169931","title":"Development and validation of a stability-indicating RP-HPLC assay method and stress degradation studies on dapiprazole.","journal":"Journal of chromatographic science"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Baradaina Llc"],"status":"approved","companyName":"Fera Pharms","companyId":"fera-pharms","modality":"Small molecule","firstApprovalDate":"1990","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1990-12-31T00:00:00.000Z","mah":"FERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1990-12-31T00:00:00.000Z","mah":"FERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1990-12-31T00:00:00.000Z","mah":"FERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1990-12-31T00:00:00.000Z","mah":"FERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1990-12-31T00:00:00.000Z","mah":"FERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-12-31T00:00:00.000Z","mah":"FERA PHARMS","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:09.637335+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":false,"score":2}}